Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Angelo de Claro

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Clinical Cancer Research

Cancer Research

English

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

Cancer Research

English

Related publications

Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma

Hematological Oncology

Cancer Research

English

Safety and Efficacy of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphomas

Therapeutic Advances in Hematology

English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology

English

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia With an Isocitrate Dehydrogenase-1 Mutation

Clinical Cancer Research

Cancer Research

English

Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma

American Journal of Hematology

English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology

English

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Hematological Oncology

Cancer Research

English

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

BioMed Research International

Molecular Biology

English

Outcomes of Patients ≥ 65 Years of Age in Zuma-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma

Hematological Oncology

Cancer Research

English